Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage

British Journal of Pharmacology

Volumn 165, Issue 2, 2012, Pages 494-505

  Chen, S H ^a,b,c   Wu, H M ^a,b,c,d,e   Ossola, B ^c   Schendzielorz, N ^c   Wilson, B C ^c   Chu, C H ^a,b,c   Chen, S L ^a,b   Wang, Q ^c   Zhang, D ^c   Qian, L ^c   Li, X ^c   Hong, Jau Shyong ^c   Lu, Ru Band ^a,b,f  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

HDAC; neurodegenerative disease; neuroprotection; neurotrophic factors; Parkinson's disease; SAHA

Indexed keywords

NEUROTOXIN; NEUROTROPHIC FACTOR; VORINOSTAT;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG CYTOTOXICITY; DRUG INDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIA CELL; IN VITRO STUDY; MESENCEPHALON; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; CELL SURVIVAL; CELLS, CULTURED; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; MESENCEPHALON; MICROGLIA; NEUROPROTECTIVE AGENTS; PREGNANCY; RATS; RATS, INBRED F344;

EID: 83755224359     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01575.x     Document Type: Article

References (47)

1. Abel T, Zukin RS, (2008). Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol 8: 57-64.
2. Baquet ZC, Bickford PC, Jones KR, (2005). Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 25: 6251-6259. (Pubitemid 40923492)
3. Block ML, Hong JS, (2005). Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76: 77-98. (Pubitemid 41242883)
4. Block ML, Zecca L, Hong JS, (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69. (Pubitemid 46011999)
5. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, et al,. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170.
6. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, et al,. (2006). Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11: 1116-1125. (Pubitemid 44867481)
7. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT, (2009). Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32: 591-601.
8. Darlington CL, (2005). Astrocytes as targets for neuroprotective drugs. Curr Opin Investig Drugs 6: 700-703. (Pubitemid 40904040)
9. Dauer W, Przedborski S, (2003). Parkinson's disease: mechanisms and models. Neuron 39: 889-909. (Pubitemid 37130207)
10. Dokmanovic M, Clarke C, Marks PA, (2007). Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981-989. (Pubitemid 350080267)
11. Fahn S, Przedborski S, (2005). Parkinsonism. In:, Rowland LP, (ed.). Merritt's Neurology, 11th edn. Lippincott Williams & Wilkins: New York, pp. 828-846.
12. Gao HM, Hong JS, (2008). Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 29: 357-365.
13. Gao HM, Hong JS, Zhang W, Liu B, (2002a). Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22: 782-790. (Pubitemid 34141759)
14. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B, (2002b). Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81: 1285-1297. (Pubitemid 34809262)
15. Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF, (2004). Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med 5: 235-241. (Pubitemid 40125304)
16. Hahnen E, Eyupoglu IY, Brichta L, Haastert K, Trankle C, Siebzehnrubl FA, et al,. (2006). In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 98: 193-202. (Pubitemid 43882944)
17. He DY, McGough NN, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, et al,. (2005). Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 25: 619-628.
18. Hisaoka K, Nishida A, Koda T, Miyata M, Zensho H, Morinobu S, et al,. (2001). Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 79: 25-34. (Pubitemid 32946639)
19. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, et al,. (2003). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 100: 2041-2046. (Pubitemid 36254570)
20. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al,. (2006). Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15: 965-977. (Pubitemid 43338237)
21. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, et al,. (2000). Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 166: 127-135.
22. Jiang Y, Langley B, Lubin FD, Renthal W, Wood MA, Yasui DH, et al,. (2008). Epigenetics in the nervous system. J Neurosci 28: 11753-11759.
23. Kazantsev AG, Thompson LM, (2008). Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 7: 854-868.
24. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al,. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23: 3923-3931. (Pubitemid 46218695)
25. Kirik D, Georgievska B, Bjorklund A, (2004). Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 7: 105-110. (Pubitemid 38129784)
26. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, et al,. (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46: 419-424. (Pubitemid 29416283)
27. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F, (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132. (Pubitemid 23186789)
28. Liu B, Hong JS, (2003). Primary rat mesencephalic neuron-glia, neuron-enriched, microglia-enriched, and astroglia-enriched cultures. Methods Mol Med 79: 387-395.
29. Liu B, Du L, Hong JS, (2000). Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293: 607-617. (Pubitemid 30244114)
30. Liu Y, Qin L, Wilson BC, An L, Hong JS, Liu B, (2002). Inhibition by naloxone stereoisomers of beta-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther 302: 1212-1219. (Pubitemid 34920245)
31. Manfredsson FP, Okun MS, Mandel RJ, (2009). Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Curr Gene Ther 9: 375-388.
32. Marks PA, (2007). Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356. (Pubitemid 46328465)
33. Marks PA, Richon VM, Rifkind RA, (2000). Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216. (Pubitemid 30627729)
34. Mena MA, de Bernardo S, Casarejos MJ, Canals S, Rodriguez-Martin E, (2002). The role of astroglia on the survival of dopamine neurons. Mol Neurobiol 25: 245-263. (Pubitemid 34665093)
35. Nicklas WJ, Vyas I, Heikkila RE, (1985). Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36: 2503-2508. (Pubitemid 15072756)
36. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, et al,. (2003). Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60: 69-73. (Pubitemid 36070646)
37. Peterson AL, Nutt JG, (2008). Treatment of Parkinson's disease with trophic factors. Neurother 5: 270-280. (Pubitemid 351454059)
38. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al,. (2007). Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462. (Pubitemid 46383175)
39. Ralay Ranaivo H, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ, et al,. (2006). Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 26: 662-670. (Pubitemid 43237131)
40. Saavedra A, Baltazar G, Duarte EP, (2008). Driving GDNF expression: the green and the red traffic lights. Prog Neurobiol 86: 186-215.
41. Saha RN, Pahan K, (2006). HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 13: 539-550.
42. Sandhu JK, Gardaneh M, Iwasiow R, Lanthier P, Gangaraju S, Ribecco-Lutkiewicz M, et al,. (2009). Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiol Dis 33: 405-414.
43. Siegel GJ, Chauhan NB, (2000). Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 33: 199-227.
44. Spiller SE, Ravanpay AC, Hahn AW, Olson JM, (2006). Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol 79: 259-270. (Pubitemid 44363729)
45. Teismann P, Tieu K, Cohen O, Choi DK, Wu DC, Marks D, et al,. (2003). Pathogenic role of glial cells in Parkinson's disease. Mov Disord 18: 121-129. (Pubitemid 36305454)
46. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, et al,. (1995). Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335-339.
47. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, et al,. (2008). Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 11: 1123-1134.